SD 133
Alternative Names: SD-133; STT-011Latest Information Update: 28 Sep 2024
At a glance
- Originator STCube Pharmaceuticals
- Developer Georgetown University; STCube Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Pancreatic cancer
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for preclinical development in Pancreatic-cancer in South Korea
- 26 Aug 2020 SD 133 is available for licensing as of 26 Aug 2020. http://www.stcube.com/e_sub05/sub01.php
- 26 Aug 2020 Preclinical trials in Pancreatic cancer in South Korea (unspecified route) (STCube Pharmaceuticals pipeline, August 2020)